Loiasis Clinical Trial
Official title:
Loiasis Cross-reactive Antigenemia and Treatment-related Adverse Events
This study seeks to determine which Loa loa antigens are released into circulation when infected individuals are treated with ivermectin.
A cohort of up to 50 participants with Loa loa microfilarial levels between 5,000 and 18,000 per ml/blood will be treated with ivermectin in an inpatient setting. Participants will be monitored for treatment-related adverse events for seven days post-treatment, and will have blood drawn on days 0, 1, 2, 3, and 7 post-treatment to assess for microfilarial load, cytokine, and antigen levels. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02644525 -
Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa Loa
|
Phase 2 | |
| Not yet recruiting |
NCT04035174 -
Evaluation of the Diagnosis Performances of DEC LTS-2 Skin Patch for Onchocerciasis in Central Africa
|
N/A | |
| Active, not recruiting |
NCT04258670 -
Spontaneous Antigenemia in Loiasis
|
||
| Completed |
NCT04049630 -
Clinical Trial Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic Patients
|
Phase 2 | |
| Active, not recruiting |
NCT04049851 -
Clinical Trial Evaluating the Safety and Efficacy of Moxidectin 2 mg Ivermectin-controlled in Loa Loa Microfilaremic Patients
|
Phase 2 | |
| Not yet recruiting |
NCT06350851 -
Development of a New Rapid Diagnostic Test to Support Onchocerciasis Elimination
|
N/A | |
| Completed |
NCT01111305 -
Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis
|
Phase 2 | |
| Not yet recruiting |
NCT06252961 -
A 3- to 5-day Clinical Trial of Levamisole in Loiasis Infected Subjects
|
Phase 2/Phase 3 |